Evidence map›Paper›PMID 37325423›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2023

Promising Modulatory Effects of Cenicriviroc on the Progression of Mouse Colorectal Cancer through Inhibition of CCR2_CCL2 Signaling Pathway.

Mina Eslami, Farid Azizi Jalilian, Rezvan Najafi, Ali Mahdavinezhad, Razieh Amini

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 71% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mina EslamiMolecular Medicine Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0009-0008-4348-2990
Farid Azizi JalilianMolecular Medicine Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0003-3134-1441
Rezvan NajafiMolecular Medicine Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0003-1326-1288
Ali MahdavinezhadMolecular Medicine Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0002-1314-8229
Razieh AminiMolecular Medicine Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0002-7588-3552
Hamedan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study was designed to assay the efficacy of cenicriviroc (CVC) on the progression of mouse colorectal cancer by downregulation of CCR2_CCL2. In this study, CVC was used to inhibit the CCR2 receptor. Next, an MTT assay was performed to evaluate the cytotoxic effects of CVC on the CT26 cell line. CT26 cells were implanted subcutaneously in BALB/c mice. After tumor implantation, one group of animals received 20 mg/kg of CVC several times. The mRNA levels of CCR2, CCL2, VEGF, NF-

Identifiers

PMID37325423
PMCPMC10264134
OpenAlexW4379535062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.